Phentermine and Topiramate Extended Release (Qsymia™)

Oct 9, 2012Drugs

Phentermine and extended-release topiramate (Qsymia™): first worldwide approval

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Vivus' oral capsule combining phentermine and extended-release topiramate is approved for obesity treatment.

Phentermine acts as an appetite suppressant, while topiramate is used to treat epilepsy.
Qsymia™, the once-daily formulation, is intended to promote weight loss by reducing appetite and enhancing feelings of fullness.
The product is also being investigated for potential use in treating sleep apnea and type 2 diabetes.
The article outlines key milestones in the development of the phentermine/topiramate combination leading to its obesity treatment approval.

AI simplified

Vivus' proprietary oral capsule containing phentermine and extended-release (ER) topiramate has been approved in the US for the treatment of obesity. Phentermine is an appetite suppressant, while topiramate is an anti-epileptic medication. The once-daily formulation, known as Qsymia™, is designed to produce weight loss by decreasing appetite and increasing satiety. The product is also in clinical development for sleep apnoea syndrome and type 2 diabetes mellitus. This article summarizes the milestones in the development of phentermine/topiramate ER leading to this first approval for obesity.

Phentermine and Topiramate Extended Release (Qsymia™)

Abstract

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief